Literature DB >> 16289252

Huntingtin fragmentation and increased caspase 3, 8 and 9 activities in lymphoblasts with heterozygous and homozygous Huntington's disease mutation.

Vittorio Maglione1, Milena Cannella, Roberto Gradini, Giuliana Cislaghi, Ferdinando Squitieri.   

Abstract

Huntington's disease (HD) is caused by mutated huntingtin (htt), a toxic protein ubiquitously expressed in nervous and non-nervous system tissues. Fragmentation of htt by caspases and further accumulation in cells of protein aggregates contribute to cell dysfunction and death. In the attempt to elucidate whether this mechanism depends on patients' genotype, we analysed the pattern of htt fragmentation, the caspase 3, 8 and 9 activities and their variation in lymphoblasts with heterozygous and homozygous CAG mutation and in controls. Cells homozygous for expanded mutation showed greater amount of mutated fragments than heterozygotes and controls, caspase 3, 8 and 9 activities greater in mutated than control cell lines, after cyanide treatment, the caspase 3 and 8 particularly increased in homozygotes. This data offers a biological explanation to the clinical in-patients evidence of mutation homozygosity associated with more severe phenotype.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16289252     DOI: 10.1016/j.mad.2005.09.011

Source DB:  PubMed          Journal:  Mech Ageing Dev        ISSN: 0047-6374            Impact factor:   5.432


  12 in total

1.  Genotype-, aging-dependent abnormal caspase activity in Huntington disease blood cells.

Authors:  Ferdinando Squitieri; Vittorio Maglione; Sara Orobello; Francesco Fornai
Journal:  J Neural Transm (Vienna)       Date:  2011-04-26       Impact factor: 3.575

Review 2.  Chipping away at diagnostics for neurodegenerative diseases.

Authors:  Clemens R Scherzer
Journal:  Neurobiol Dis       Date:  2009-03-10       Impact factor: 5.996

Review 3.  An in vitro perspective on the molecular mechanisms underlying mutant huntingtin protein toxicity.

Authors:  G Cisbani; F Cicchetti
Journal:  Cell Death Dis       Date:  2012-08-30       Impact factor: 8.469

4.  Metabolic state determines sensitivity to cellular stress in Huntington disease: normalization by activation of PPARγ.

Authors:  Youngnam N Jin; Woong Y Hwang; Chulman Jo; Gail V W Johnson
Journal:  PLoS One       Date:  2012-01-20       Impact factor: 3.240

5.  De novo Synthesis of Sphingolipids Is Defective in Experimental Models of Huntington's Disease.

Authors:  Alba Di Pardo; Abdul Basit; Andrea Armirotti; Enrico Amico; Salvatore Castaldo; Giuseppe Pepe; Federico Marracino; Fabio Buttari; Anna F Digilio; Vittorio Maglione
Journal:  Front Neurosci       Date:  2017-12-19       Impact factor: 4.677

6.  Age-associated chromatin relaxation is enhanced in Huntington's disease mice.

Authors:  Myungsun Park; Byungkuk Min; Kyuheum Jeon; Sunwha Cho; Jung Sun Park; Jisun Kim; Jeha Jeon; Jinhoi Song; Seokho Kim; Sangkyun Jeong; Hyemyung Seo; Yong-Kook Kang
Journal:  Aging (Albany NY)       Date:  2017-03-12       Impact factor: 5.682

Review 7.  Chaperones in Polyglutamine Aggregation: Beyond the Q-Stretch.

Authors:  E F E Kuiper; Eduardo P de Mattos; Laura B Jardim; Harm H Kampinga; Steven Bergink
Journal:  Front Neurosci       Date:  2017-03-23       Impact factor: 4.677

8.  Stimulation of Sphingosine Kinase 1 (SPHK1) Is Beneficial in a Huntington's Disease Pre-clinical Model.

Authors:  Alba Di Pardo; Giuseppe Pepe; Salvatore Castaldo; Federico Marracino; Luca Capocci; Enrico Amico; Michele Madonna; Susy Giova; Se Kyoo Jeong; Bu-Mahn Park; Byeong Deog Park; Vittorio Maglione
Journal:  Front Mol Neurosci       Date:  2019-04-24       Impact factor: 5.639

9.  Huntingtin promotes cell survival by preventing Pak2 cleavage.

Authors:  Shouqing Luo; David C Rubinsztein
Journal:  J Cell Sci       Date:  2009-02-24       Impact factor: 5.285

Review 10.  Sphingolipid Metabolism: A New Therapeutic Opportunity for Brain Degenerative Disorders.

Authors:  Alba Di Pardo; Vittorio Maglione
Journal:  Front Neurosci       Date:  2018-04-17       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.